Novel gene therapy offers potential treatment for FCMD
Japanese researchers proposed using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama Muscular Dystrophy (FCMD).
List view / Grid view
Japanese researchers proposed using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama Muscular Dystrophy (FCMD).
Join our experts as they discuss factors causing variability issues in organoids and how to avoid them.
US researchers have utilised a cancer immunotherapy technique, CAR-T cell method to effectively eliminate SARS-CoV-2 virus pre- and post-infection in vitro.
South Korean researchers identified two saponins there were highly effective in blocking the ability of SARS-CoV-2 variants to enter cells.
In this article, Drug Target Review’s Ria Kakkad shares some of the most recent progress in discovering a drug for COPD, a disease that remains a major challenge in the medical industry.
Scientists have developed a new strategy to generate hair follicles in vitro with potential useful applications for treating hair loss, animal testing and drug screening.
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
A new study has shown how tau weakens transmission across synapses in the brains of mice, providing insight into Alzheimer's.
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
7 September 2022 | By Sartorius
Watch this webinar to hear from Dr Yuansheng Yang as he introduces a CHO cell-based technology allowing simultaneous display and secretion of antibodies for accelerating the process of antibody development.
Scientists have identified a molecule that can bind to a lethal subtype of the bacterial Shiga toxin, suppressing its deadly effects.
4 July 2022 | By Eurofins Discovery
In this on-demand webinar, an assay strategy to assess transport-mediated drug interactions that complies with regulations is examined.
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Michael Grange, Tomography Group Leader from the Rosalind Franklin Institute (RFI), UK about the advantages of using cryo-electron tomography imaging.
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
Drug testing on advanced cell-based models such as organoids has gained in popularity, but significant technical hurdles remain that prevent further assay miniaturisation and higher assay throughput. Through the replacement of animal-derived basement membranes with wood-derived nanofibrillar cellulose hydrogel (NFC), Dr Tijmen Booij and Dr Christian Stirnimann from ETH Zurich,…